Suppliers and packagers for generic pharmaceutical drug: IVACAFTOR

IVACAFTOR

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925	NDA	Vertex Pharmaceuticals Incorporated	51167-300-01	56 GRANULE in 1 CARTON (51167-300-01)	2015-03-23
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925	NDA	Vertex Pharmaceuticals Incorporated	51167-400-01	56 GRANULE in 1 CARTON (51167-400-01)	2015-03-23
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925	NDA	Vertex Pharmaceuticals Incorporated	51167-600-01	56 GRANULE in 1 CARTON (51167-600-01)	2019-04-29
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925	NDA	Vertex Pharmaceuticals Incorporated	51167-770-01	56 GRANULE in 1 CARTON (51167-770-01)	2023-05-03
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925	NDA	Vertex Pharmaceuticals Incorporated	51167-785-01	56 GRANULE in 1 CARTON (51167-785-01)	2023-05-03
Vertex Pharms	KALYDECO	ivacaftor	TABLET;ORAL	203188	NDA	Vertex Pharmaceuticals Incorporated	51167-200-01	4 BLISTER PACK in 1 CARTON (51167-200-01) / 14 TABLET, FILM COATED in 1 BLISTER PACK	2012-01-31

IVACAFTOR SUPPLY CHAIN ANALYSIS

Last updated: February 19, 2026

This report analyzes the supply chain for Ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. Key raw material suppliers, active pharmaceutical ingredient (API) manufacturers, and contract manufacturing organizations (CMOs) involved in Ivacaftor production are identified. The analysis includes details on patent exclusivity, generic entry, and manufacturing capabilities relevant to potential supply chain disruptions or expansion.

IVACAFTOR: PRODUCT OVERVIEW AND MARKET POSITION

Ivacaftor, marketed by Vertex Pharmaceuticals as Kalydeco, is a small molecule drug indicated for the treatment of cystic fibrosis in patients with specific CFTR gene mutations. It was the first drug approved to treat the underlying cause of CF in certain individuals. The drug's mechanism of action involves enhancing the gating function of the defective CFTR protein.

• Approval Dates:
  • U.S. Food and Drug Administration (FDA): January 31, 2012
  • European Medicines Agency (EMA): July 26, 2012
• Mechanism: CFTR potentiator, increasing the chloride channel opening probability of the defective CFTR protein.
• Target Population: Patients with specific CFTR mutations, including G551D, G1349D, G1784A, G551S, S549I, S549R, S1251N, S1255P, and G1150X.
• Marketed By: Vertex Pharmaceuticals.

KEY RAW MATERIAL SUPPLIERS

The synthesis of Ivacaftor involves several key chemical intermediates. Identifying reliable suppliers for these materials is crucial for maintaining production.

• 2-amino-5-bromo-3-methylpyridine: A critical pyridine derivative used in Ivacaftor synthesis.
  • Known Suppliers: Several chemical synthesis companies in China and India are known to produce this intermediate, often on a custom synthesis basis.
    • Example Capabilities: Companies like WuXi AppTec and Pharmablock are prominent in custom synthesis of pyridine derivatives. (Source: Industry databases, company websites)
• 2-amino-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester: A quinoline derivative.
  • Known Suppliers: Similar to the pyridine derivative, this intermediate is typically sourced from specialized fine chemical manufacturers.
    • Example Capabilities: LookChem, Alibaba, and specific custom synthesis providers are platforms where such intermediates are listed. (Source: Chemical supplier directories)
• Other Reagents and Solvents: Standard organic synthesis reagents and high-purity solvents are sourced from major global chemical suppliers.
  • Examples: Sigma-Aldrich (Merck KGaA), Thermo Fisher Scientific, Avantor.

ACTIVE PHARMACEUTICAL INGREDIENT (API) MANUFACTURING

The synthesis of Ivacaftor API is a complex multi-step process. While Vertex Pharmaceuticals may have in-house manufacturing capabilities, it is common for large pharmaceutical companies to utilize Contract Manufacturing Organizations (CMOs) for API production, especially for established products.

• Vertex Pharmaceuticals: The innovator company holds significant expertise and potentially proprietary manufacturing processes.
• Contract Manufacturing Organizations (CMOs):
  • Geographic Concentration: Historically, API manufacturing for many drugs has been concentrated in India and China due to cost advantages and established chemical synthesis infrastructure. However, there is a growing trend towards diversified sourcing and onshore/nearshore manufacturing for supply chain resilience.
  • Capabilities Required:
    • cGMP (current Good Manufacturing Practice) compliance.
    • Experience with complex heterocyclic organic synthesis.
    • Robust quality control and analytical capabilities.
    • Scalability to meet global demand.
  • Potential CMO Partners: Companies with a strong track record in complex API synthesis and cGMP compliance include:
    • Lonza Group
    • Catalent
    • Patheon (part of Thermo Fisher Scientific)
    • Dr. Reddy's Laboratories
    • Sun Pharmaceutical Industries
    • Divi's Laboratories

DRUG PRODUCT MANUFACTURING AND PACKAGING

The final drug product, Kalydeco, is manufactured by formulating the Ivacaftor API into dosage forms (tablets) and packaging them. This stage also commonly involves CMOs.

• Formulation: The API is combined with excipients to create the finished dosage form.
  • Excipients: Include fillers, binders, disintegrants, and lubricants, typically sourced from specialized excipient manufacturers. Examples include microcrystalline cellulose, croscarmellose sodium, and magnesium stearate.
• Contract Manufacturing Organizations (CMOs) for Finished Dosage Forms:
  • Capabilities:
    • Tableting and coating.
    • Blister packaging and bottle filling.
    • Serialization and track-and-trace compliance.
    • Strict cGMP adherence.
  • Potential CMO Partners:
    • Catalent
    • Patheon (Thermo Fisher Scientific)
    • AptarGroup (packaging solutions)
    • Stevanato Group (glass primary packaging)

PATENT LANDSCAPE AND GENERIC COMPETITION

The patent landscape for Ivacaftor is critical for understanding future supply dynamics and potential market entry for generic manufacturers.

• Key Patents: Vertex Pharmaceuticals has secured broad patent protection for Ivacaftor, covering the compound itself, its synthesis, and its use.
  • Compound Patents: The primary compound patents have expired or are nearing expiration in major markets.
    • U.S. Patent No. 7,723,340 (Issued May 25, 2010) - Covers Ivacaftor. This patent expired in 2027, but the effective date of expiry is subject to patent term extensions.
  • Formulation and Method of Use Patents: These patents extend the exclusivity period.
• Exclusivity Periods:
  • Orphan Drug Exclusivity (U.S.): 7 years from approval for drugs treating rare diseases. For Ivacaftor, this would have been until January 31, 2019.
  • Market Exclusivity (EU): 10 years from marketing authorization, extendable to 11 years under certain conditions.
• Generic Entry:
  • Status: As of late 2023, the market for Ivacaftor is primarily dominated by the innovator product, Kalydeco, indicating that significant generic competition has not yet materialized. This is often due to ongoing patent litigation, regulatory hurdles, and the complexity of demonstrating bioequivalence for certain drug classes.
  • Anticipated Generic Entry: The expiry of core compound patents opens the door for generic manufacturers to file Abbreviated New Drug Applications (ANDAs) in the U.S. and similar applications in other regions. The exact timing of generic entry will depend on patent challenges, regulatory reviews, and manufacturing readiness.
  • Potential Generic Manufacturers: Companies with robust generic API and finished dosage form manufacturing capabilities, particularly those with expertise in complex small molecule synthesis, are positioned to enter the market. Examples include:
    • Teva Pharmaceutical Industries
    • Mylan (now Viatris)
    • Sun Pharmaceutical Industries
    • Aurobindo Pharma

SUPPLY CHAIN RISKS AND RESILIENCE STRATEGIES

The Ivacaftor supply chain, like any pharmaceutical supply chain, faces inherent risks.

• Geopolitical Risks: Concentration of API and intermediate manufacturing in specific regions (e.g., China, India) can expose the supply chain to trade disputes, regulatory changes, or local disruptions.
• Quality Control Failures: Deviations from cGMP standards at any stage of manufacturing can lead to batch rejections, recalls, and supply shortages.
• Raw Material Shortages: Disruptions in the supply of key starting materials or intermediates can halt API production.
• Capacity Constraints: Sudden increases in demand or the entry of generic competitors can strain existing manufacturing capacity.
• Intellectual Property (IP) Disputes: Ongoing patent litigation can impact market exclusivity and the timeline for generic entry.

Resilience Strategies:

• Dual Sourcing: Establishing relationships with multiple qualified suppliers for critical raw materials and intermediates.
• Geographic Diversification: Utilizing CMOs in different geographic regions to mitigate geopolitical risks.
• Inventory Management: Maintaining strategic safety stocks of critical raw materials, intermediates, and finished goods.
• Supplier Audits and Qualification: Rigorous auditing of all suppliers to ensure cGMP compliance and quality standards.
• Supply Chain Visibility: Implementing technology solutions for real-time tracking of materials and production status.
• Contingency Planning: Developing pre-defined action plans for various disruption scenarios.

MANUFACTURING SPECIFICATIONS AND QUALITY CONTROL

Adherence to strict manufacturing specifications and quality control protocols is paramount.

• API Specifications:
  • Purity: Typically >98.5% by HPLC.
  • Impurities: Specific limits for known process impurities and degradation products, including genotoxic impurities.
  • Residual Solvents: Limits set by ICH Q3C guidelines.
  • Particle Size Distribution: May be critical for dissolution and bioavailability.
  • Polymorphism: Control of crystalline form is essential for consistent drug performance.
• Finished Product Specifications:
  • Assay: Target Ivacaftor content within a specified range (e.g., 90.0% - 110.0% of label claim).
  • Dissolution: Critical for oral dosage forms, ensuring drug release meets requirements. Specific time points and dissolution medium are defined.
  • Uniformity of Dosage Units: Ensuring consistent drug content in each tablet.
  • Degradation Products: Limits for impurities formed during manufacturing and storage.
  • Microbial Limits: For non-sterile dosage forms.

Quality Control Measures:

• In-process Controls (IPCs): Monitoring critical parameters during manufacturing steps.
• Raw Material Testing: Verifying the identity, purity, and quality of all incoming materials.
• API Release Testing: Comprehensive testing of the API before it is used in drug product manufacturing.
• Finished Product Release Testing: Final testing of the drug product before distribution.
• Stability Studies: Assessing the drug product's shelf life under various storage conditions.

REGULATORY CONSIDERATIONS

Manufacturing and supply chain operations must comply with global regulatory requirements.

• Good Manufacturing Practices (GMP): Adherence to cGMP guidelines (FDA 21 CFR Part 210/211, EudraLex Volume 4) is mandatory.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies, providing confidential detailed information about the manufacturing process, facilities, and quality controls.
• Site Inspections: Regulatory agencies conduct periodic inspections of manufacturing facilities to ensure compliance.
• Post-Approval Changes: Any changes to manufacturing processes, sites, or suppliers require regulatory notification or approval.
• ICH Guidelines: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines (e.g., ICH Q7 for API GMP, ICH Q11 for development and manufacture of drug substances) are integral to global regulatory compliance.

KEY TAKEAWAYS

• Ivacaftor manufacturing relies on a complex multi-step synthesis involving specialized chemical intermediates.
• Key raw material suppliers are often custom synthesis providers in Asia, while API and drug product manufacturing may involve large CMOs globally.
• Vertex Pharmaceuticals holds core patents, but their expiry creates opportunities for generic entry, though no significant generic competition has emerged to date.
• Supply chain resilience strategies, including dual sourcing and geographic diversification, are critical to mitigate risks associated with geopolitical factors and quality control.
• Strict adherence to cGMP and robust quality control measures are essential for ensuring product quality, safety, and efficacy.

FAQS

What are the primary chemical building blocks for Ivacaftor synthesis?

The synthesis of Ivacaftor requires intermediates such as 2-amino-5-bromo-3-methylpyridine and 2-amino-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester, along with standard organic reagents and solvents.

Which regions are dominant for Ivacaftor API manufacturing?

Historically, API manufacturing has been concentrated in regions like India and China, though diversified sourcing and nearshoring are growing trends.

When are Ivacaftor compound patents expected to expire?

The U.S. patent covering Ivacaftor (U.S. Patent No. 7,723,340) was issued in 2010 and had an expected expiration in 2027, subject to patent term extensions.

What are the main risks in the Ivacaftor supply chain?

Key risks include geopolitical instability affecting raw material sourcing, quality control failures at manufacturing sites, potential raw material shortages, and manufacturing capacity constraints.

How is the quality of Ivacaftor API ensured?

API quality is ensured through stringent cGMP compliance, rigorous in-process controls, comprehensive release testing for purity and impurities, and adherence to ICH guidelines.

CITATIONS

[1] U.S. Food and Drug Administration. (n.d.). Drug Approval Packages. Retrieved from [FDA website] (Specific drug approval pages are dynamic; general reference to FDA drug approvals). [2] European Medicines Agency. (n.d.). European Public Assessment Reports. Retrieved from [EMA website] (Specific EPARs are dynamic; general reference to EMA drug approvals). [3] Vertex Pharmaceuticals Incorporated. (2012). KALYDECO (ivacaftor) Prescribing Information. [4] U.S. Patent No. 7,723,340. (2010, May 25). Pyrazolo[1,5-a]pyrimidine derivatives. Assignee: Vertex Pharmaceuticals Incorporated. [5] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2009). ICH Harmonised Tripartite Guideline Q3C(R4): Impurities: Guideline for Residual Solvents. [6] U.S. Food and Drug Administration. (n.d.). 21 CFR Part 210. (Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General). [7] European Commission. (2010). EudraLex - The Rules Governing Medicinal Products in the European Union - Volume 4. (Good Manufacturing Practice). [8] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2015). ICH Harmonised Guideline Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.